LifeSci Capital analyst Sam Slutsky has maintained their bullish stance on ATXS stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sam Slutsky has given his Buy rating due to a combination of factors surrounding Astria Therapeutics. The company recently secured a licensing agreement with Kaken Pharmaceutical for the development and commercialization of navenibart in Japan, which includes an upfront payment of $16 million and potential milestone payments. This partnership not only extends Astria’s cash runway into 2028 but also aligns with a reputable partner in the Japanese market, enhancing the company’s financial stability and strategic positioning.
Additionally, Astria’s ongoing Phase 3 ALPHA-ORBIT trial for navenibart as a prophylactic treatment for hereditary angioedema (HAE) is a significant factor. The trial, which began in early 2025, is designed to assess the efficacy of navenibart with multiple dosing cohorts and includes a comprehensive analysis of HAE attack reduction. With topline data expected in early 2027, the trial’s progress and potential success could further bolster Astria’s market position and justify the Buy rating.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $16.00 price target.